Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude+Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Ascendis Pharma A/S - Ordinary Share
(NQ:
ASND
)
219.75
+2.96 (+1.37%)
Streaming Delayed Price
Updated: 2:07 PM EDT, Jun 4, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Ascendis Pharma A/S - Ordinary Share
< Previous
1
2
3
4
5
6
7
8
9
Next >
Loar Holdings Posts Upbeat Results, Joins Nvidia, Clean Energy Fuels, Penumbra And Other Big Stocks Moving Higher On Tuesday
↗
August 13, 2024
Via
Benzinga
Ascendis' Hypoparathyroidism Drug Scores FDA Approval As First and Only Treatment, Replacing Takeda's Drug Discontinued Due To Supply Issues
↗
August 12, 2024
FDA grants approval to Ascendis Pharma's Yorvipath (TransCon PTH) for adult hypoparathyroidism. Yorvipath offers continuous parathyroid hormone exposure and is set to launch in the U.S. with patient...
Via
Benzinga
Ascendis Pharma Zips Higher After FDA Approves Embattled Thyroid Drug
↗
August 12, 2024
The company faced a number of regulatory setbacks that pushed its initial expected approval date out from April.
Via
Investor's Business Daily
$100 Invested In This Stock 10 Years Ago Would Be Worth $5,900 Today
↗
August 09, 2024
Via
Benzinga
$1000 Invested In Ascendis Pharma 10 Years Ago Would Be Worth This Much Today
↗
July 18, 2024
Via
Benzinga
Here's How Much $1000 Invested In Ascendis Pharma 15 Years Ago Would Be Worth Today
↗
July 03, 2024
Via
Benzinga
Here's How Much You Would Have Made Owning Ascendis Pharma Stock In The Last 15 Years
↗
June 26, 2024
Via
Benzinga
If You Invested $100 In This Stock 15 Years Ago, You Would Have $4,100 Today
↗
May 31, 2024
Via
Benzinga
Macy's, Ascendis Pharma And 3 Stocks To Watch Heading Into Friday
↗
July 05, 2024
U.S. stock futures rise, Macy's receives higher offer, LGI Homes sells 571 homes, Telefonaktiebolaget records impairment charge, GFL declares dividend.
Via
Benzinga
(ASND) - Analyzing Ascendis Pharma's Short Interest
↗
May 28, 2024
Via
Benzinga
$100 Invested In This Stock 10 Years Ago Would Be Worth $6,500 Today
↗
May 17, 2024
Via
Benzinga
FDA Pushes Review Date For Ascendis Pharma's Hormone Disorder Candidate By Three Months
↗
May 15, 2024
Ascendis Pharma announces FDA's extension of the review date for TransCon PTH for adults with hypoparathyroidism to August 14, 2024. TransCon PTH aims to address low calcium levels due to...
Via
Benzinga
Masters In Trading - Saturday, May 11
↗
May 11, 2024
In this recap of the most recent trading session, I discuss earnings results and the market rally seen throughout the past week.
Via
Talk Markets
$100 Invested In Ascendis Pharma 15 Years Ago Would Be Worth This Much Today
↗
May 06, 2024
Via
Benzinga
ASND Stock Earnings: Ascendis Pharma Reported Results for Q1 2024
↗
May 02, 2024
Ascendis Pharma just reported results for the first quarter of 2024.
Via
InvestorPlace
Looking Into Ascendis Pharma's Recent Short Interest
↗
April 26, 2024
Via
Benzinga
$1000 Invested In Ascendis Pharma 15 Years Ago Would Be Worth This Much Today
↗
April 18, 2024
Via
Benzinga
Week In Review: ProfoundBio, A Seattle-Suzhou ADC Biotech, Acquired By Genmab For $1.8 Billion
↗
April 06, 2024
ProfoundBio will be acquired by Copenhagen’s Genmab A/S in a $1.8 billion all-cash deal. The acquisition will expand Genmab’s drug portfolio, including three ProfoundBio clinical stage ADC candidates...
Via
Talk Markets
Here's How Much You Would Have Made Owning Ascendis Pharma Stock In The Last 10 Years
↗
April 03, 2024
Via
Benzinga
Here's How Much $100 Invested In Ascendis Pharma 15 Years Ago Would Be Worth Today
↗
March 14, 2024
Via
Benzinga
5 Biotechnology Stocks To Buy For A Stable Portfolio In 2024
↗
March 09, 2024
Things have been looking better for the biotech industry in 2024 after a decent performance in 2023. Here is a look at some biotech stocks that may provide stability to one's portfolio throughout the...
Via
Talk Markets
These Five Small-Cap Stocks Under The Radar Are Expected To Surge, Says Stock Researcher
↗
March 03, 2024
Ethan Meyers, the research director at Westfield Capital Management, has a knack for identifying promising investments that have proven fruitful, especially for the Harbor Small Cap Growth Fund, where...
Via
Benzinga
$1000 Invested In This Stock 15 Years Ago Would Be Worth $45,000 Today
↗
February 23, 2024
Via
Benzinga
How Is The Market Feeling About Ascendis Pharma?
↗
February 13, 2024
Via
Benzinga
If You Invested $1000 In This Stock 10 Years Ago, You Would Have $70,000 Today
↗
February 08, 2024
Via
Benzinga
Earnings Scheduled For February 7, 2024
↗
February 07, 2024
Companies Reporting Before The Bell • Madison Square Garden (NYSE:MSGE) is expected to report quarterly loss at $0.80 per share on revenue of $301.83 million.
Via
Benzinga
Ascendis Pharma's Earnings: A Preview
↗
February 06, 2024
Via
Benzinga
$100 Invested In Ascendis Pharma 5 Years Ago Would Be Worth This Much Today
↗
February 02, 2024
Via
Benzinga
Ascendis Pharma's Growth Hormone Deficiency Candidate Outperforms in Phase 3 Trial
↗
December 19, 2023
Ascendis Pharma A/S (NASDAQ: ASND) released topline results from Phase 3 foresiGHt trial to compare the efficacy and safety of TransCon hGH (lonapegsomatropin) with placebo and daily hGH (human growth...
Via
Benzinga
Analyst Expectations for Ascendis Pharma's Future
↗
November 09, 2023
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
9
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
